Cargando…
Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database
BACKGROUND: Cilostazol has been associated with spontaneous reports of cardiovascular adverse events and serious bleeding. The objective of this study is to determine the relative risk of cardiovascular adverse events or haemorrhages in patients with peripheral artery disease treated with cilostazol...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941464/ https://www.ncbi.nlm.nih.gov/pubmed/29739318 http://dx.doi.org/10.1186/s12872-018-0822-4 |
_version_ | 1783321290412654592 |
---|---|
author | Real, Jordi Serna, M Catalina Giner-Soriano, Maria Forés, Rosa Pera, Guillem Ribes, Esther Alzamora, Maite Marsal, Josep Ramon Heras, Antonio Morros, Rosa |
author_facet | Real, Jordi Serna, M Catalina Giner-Soriano, Maria Forés, Rosa Pera, Guillem Ribes, Esther Alzamora, Maite Marsal, Josep Ramon Heras, Antonio Morros, Rosa |
author_sort | Real, Jordi |
collection | PubMed |
description | BACKGROUND: Cilostazol has been associated with spontaneous reports of cardiovascular adverse events and serious bleeding. The objective of this study is to determine the relative risk of cardiovascular adverse events or haemorrhages in patients with peripheral artery disease treated with cilostazol in comparison to pentoxifylline users. METHODS: Population-based cohort study including all individuals older than 40 who initiated cilostazol or pentoxifylline during 2009–2011 in SIDIAP database. The two treatment groups were matched through propensity score (PS). RESULTS: Nine thousand one hundred twenty-nine patients met inclusion criteria and after PS matching, there were 2905 patients in each group. 76% of patients were men, with similar mean ages in both groups (68.8 for cilostazol and 69.4 for pentoxifylline). There were no differences in bleeding, cerebrovascular and cardiovascular events between both groups. CONCLUSIONS: Patients treated with cilostazol were different from those treated with pentoxifylline at baseline, so they were matched through PS. We did not find differences between treatment groups in the incidence of bleeding or cardiovascular and cerebrovascular events. Cilostazol should be used with precaution in elderly polymedicated patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12872-018-0822-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5941464 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59414642018-05-14 Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database Real, Jordi Serna, M Catalina Giner-Soriano, Maria Forés, Rosa Pera, Guillem Ribes, Esther Alzamora, Maite Marsal, Josep Ramon Heras, Antonio Morros, Rosa BMC Cardiovasc Disord Research Article BACKGROUND: Cilostazol has been associated with spontaneous reports of cardiovascular adverse events and serious bleeding. The objective of this study is to determine the relative risk of cardiovascular adverse events or haemorrhages in patients with peripheral artery disease treated with cilostazol in comparison to pentoxifylline users. METHODS: Population-based cohort study including all individuals older than 40 who initiated cilostazol or pentoxifylline during 2009–2011 in SIDIAP database. The two treatment groups were matched through propensity score (PS). RESULTS: Nine thousand one hundred twenty-nine patients met inclusion criteria and after PS matching, there were 2905 patients in each group. 76% of patients were men, with similar mean ages in both groups (68.8 for cilostazol and 69.4 for pentoxifylline). There were no differences in bleeding, cerebrovascular and cardiovascular events between both groups. CONCLUSIONS: Patients treated with cilostazol were different from those treated with pentoxifylline at baseline, so they were matched through PS. We did not find differences between treatment groups in the incidence of bleeding or cardiovascular and cerebrovascular events. Cilostazol should be used with precaution in elderly polymedicated patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12872-018-0822-4) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-08 /pmc/articles/PMC5941464/ /pubmed/29739318 http://dx.doi.org/10.1186/s12872-018-0822-4 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Real, Jordi Serna, M Catalina Giner-Soriano, Maria Forés, Rosa Pera, Guillem Ribes, Esther Alzamora, Maite Marsal, Josep Ramon Heras, Antonio Morros, Rosa Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database |
title | Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database |
title_full | Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database |
title_fullStr | Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database |
title_full_unstemmed | Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database |
title_short | Safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database |
title_sort | safety of cilostazol in peripheral artery disease: a cohort from a primary healthcare electronic database |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941464/ https://www.ncbi.nlm.nih.gov/pubmed/29739318 http://dx.doi.org/10.1186/s12872-018-0822-4 |
work_keys_str_mv | AT realjordi safetyofcilostazolinperipheralarterydiseaseacohortfromaprimaryhealthcareelectronicdatabase AT sernamcatalina safetyofcilostazolinperipheralarterydiseaseacohortfromaprimaryhealthcareelectronicdatabase AT ginersorianomaria safetyofcilostazolinperipheralarterydiseaseacohortfromaprimaryhealthcareelectronicdatabase AT foresrosa safetyofcilostazolinperipheralarterydiseaseacohortfromaprimaryhealthcareelectronicdatabase AT peraguillem safetyofcilostazolinperipheralarterydiseaseacohortfromaprimaryhealthcareelectronicdatabase AT ribesesther safetyofcilostazolinperipheralarterydiseaseacohortfromaprimaryhealthcareelectronicdatabase AT alzamoramaite safetyofcilostazolinperipheralarterydiseaseacohortfromaprimaryhealthcareelectronicdatabase AT marsaljosepramon safetyofcilostazolinperipheralarterydiseaseacohortfromaprimaryhealthcareelectronicdatabase AT herasantonio safetyofcilostazolinperipheralarterydiseaseacohortfromaprimaryhealthcareelectronicdatabase AT morrosrosa safetyofcilostazolinperipheralarterydiseaseacohortfromaprimaryhealthcareelectronicdatabase |